Drug addiction develops into a debilitating psychiatric disorder. Changes in gene expression in brain reward systems are believed to contribute to the pathogenesis and maintenance of this condition. Recently, Increasing evidence has implicated epigenetic modifications of the genome through DNA methylation, histone modifications and non-coding RNAs (i.e., microRNAs) in many biological processes, including modification of the nervous system during learning, memory, and addiction. Such epigenetic mechanisms can integrate various environmental stimuli and cause long-term drug-induced transcriptional and behavioral changes. However, the detection of epigenetic alterations requires specialized instrumentation and expertise. It is not practical at the present time for most laboratories to become fully proficient in all aspects of experimental design and data analysis that are required to perform epigenetic genome-wide profiling. Moreover, fast-developing technology has enabled the Core to perform transcriptome analysis at the single cell level, which will certainly benefit drug addiction research, given the fact that brain reward regions are so heterogeneous. The CSORDA Epigenetics and Transcriptome Core (E/T-Core) Is newly established and with the goal of providing opportunities for drug addiction researchers to carry out epigenetic analyses (e.g., DNA methylation, histone modifications, microRNA detection), as well as advanced gene expression analyses with proficiency. The epigenetic and transcript profiling approaches can be broadly and effectively applied to drug addition studies to bring forward new important insights to advance the field.

Public Health Relevance

The E/T core provides exciting new technologies for epigenetic analysis as well as advanced gene expression analyses including single cell transcriptome profiling, which undoubtedly play an important role in the drug addiction studies.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Bakhurin, Konstantin I; Goudar, Vishwa; Shobe, Justin L et al. (2017) Differential Encoding of Time by Prefrontal and Striatal Network Dynamics. J Neurosci 37:854-870
Ehrlich, Aliza T; Semache, Meriem; Bailly, Julie et al. (2017) Mapping GPR88-Venus illuminates a novel role for GPR88 in sensory processing. Brain Struct Funct :
Lalanne, L; Ayranci, G; Filliol, D et al. (2017) Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence. Addict Biol 22:1010-1021
Dagnew, Robel; Lin, Yin-Ying; Agatep, Jerikko et al. (2017) CerebraLux: a low-cost, open-source, wireless probe for optogenetic stimulation. Neurophotonics 4:045001
Boulos, Laura-Joy; Darcq, Emmanuel; Kieffer, Brigitte Lina (2017) Translating the Habenula-From Rodents to Humans. Biol Psychiatry 81:296-305
Ben Hamida, Sami; Boulos, Laura-Joy; McNicholas, Michael et al. (2017) Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking. Addict Biol :
Charbogne, Pauline; Gardon, Olivier; Martín-García, Elena et al. (2017) Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food. Biol Psychiatry 81:778-788
Pradhan, Amynah A; Perroy, Julie; Walwyn, Wendy M et al. (2016) Agonist-Specific Recruitment of Arrestin Isoforms Differentially Modify Delta Opioid Receptor Function. J Neurosci 36:3541-51
Cahill, Catherine M; Walwyn, Wendy; Taylor, Anna M W et al. (2016) Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation. Trends Pharmacol Sci 37:963-976
Storey, Granville P; Gonzalez-Fernandez, Gabriel; Bamford, Ian J et al. (2016) Nicotine Modifies Corticostriatal Plasticity and Amphetamine Rewarding Behaviors in Mice(1,2,3). eNeuro 3:

Showing the most recent 10 out of 111 publications